A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Urothelial Cancer
Interventions
DRUG

Atezolizumab

Participants will receive 1200 mg IV atezolizumab Q3W.

DRUG

Tobemstomig

Participants will receive 600 mg IV tobemstomig Q3W.

DRUG

Tiragolumab

Participants will receive 600 mg IV tiragolumab Q3W.

Trial Locations (57)

2113

Macquarie University Hospital, Macquarie Park

2730

Herlev Hospital, Herlev

5037

ICON Cancer Care Adelaide, Kurralta Park

5112

Lyell McEwin Hospital, Adelaide

8200

Aarhus Universitetshospital, Aarhus N

20132

Irccs Ospedale San Raffaele, Milan

20246

Martini-Klinik am UKE GmbH, Hamburg

21565

Gachon University Gil Medical Center, Incheon

22030

Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne

28040

Hospital Universitario Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

28050

Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal, Madrid

34722

Goztepe Prof.Dr. Suleyman Yalcin City Hospital, Kadiköy

35101

Izmir Medical Point Hospital, Izmir

35128

IRCCS Istituto Oncologico Veneto (IOV), Padua

40138

Azienda Ospedaliero-Universitaria S.Orsola-Malpighi, Bologna

44106

Cleveland Clinic, Cleveland

47014

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola, Meldola

54007

Theageneio Hospital, Thessaloniki

69373

Centre Leon Berard, Lyon

70124

A.O. Universitaria Ospedale Consorziale Policlinico Di Bari, Bari

77030

MD Anderson Cancer Center, Houston

80131

Istituto Nazionale Tumori Irccs Fondazione G. Pascale, Napoli

94800

Gustave Roussy, Villejuif

100142

Beijing Cancer Hospital, Beijing

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

510060

Sun yat-sen University Cancer Center, Guangzhou

610047

West China Hospital - Sichuan University, Chengdu

80440-220

Hospital Universitario Evangelico De Curitiba, Curitiba

90035-903

Hospital das Clinicas - UFRGS, Porto Alegre

76834-899

Hospital de Amor Amazônia, Porto Velho

09060-650

*X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia, Santo André

01323-903

Hospital Alemao Oswaldo Cruz, São Paulo

06120

Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie, Halle

115 28

Alexandras General Hospital of Athens, Athens

124 62

Attikon University General Hospital, Chaïdári

00168

"Policlinico Universitario Agostino Gemelli", Rome

05100

Azienda Ospedaliera S. Maria - Terni, Terni

03100

Health Pharma Professional Research, Mexico City

75-581

Szpital Wojewódzki im. Miko?aja Kopernika, Koszalin

31-501

Szpital Uniwersytecki w Krakowie, Krakow

60-192

Pratia Poznan, Późna

04-073

Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o., Warsaw

Unknown

Seoul National University Bundang Hospital, Gyeonggi-do

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08035

Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona

08908

Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona

01220

Adana Baskent University Medical Faculty, Adana

06800

Ankara City Hospital, Ankara

E1 2ES

Barts and the London NHS Trust, London

SW3 6JJ

Royal Marsden Hospital, London

PR2 9HT

Royal Preston Hosptial, Preston

SM2 5PT

Royal Marsden Hospital (Sutton), Sutton

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY